LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Cost‐effectiveness of first‐line versus second‐line use of domestic anti‐PD‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer

Photo from wikipedia

Programmed cell death protein‐1/programmed cell death ligand‐1 (PD‐1/L1) inhibitor is a promising therapeutic option that can be used as either a first‐line or second‐line treatment for driver‐negative advanced or metastatic… Click to show full abstract

Programmed cell death protein‐1/programmed cell death ligand‐1 (PD‐1/L1) inhibitor is a promising therapeutic option that can be used as either a first‐line or second‐line treatment for driver‐negative advanced or metastatic squamous non‐small cell lung cancers (sqNSCLC). However, reuse of PD‐1/L1 inhibitor in second‐line beyond progression after the first‐line is generally not recommended. Therefore, oncologists face challenges in making a proper decision of using PD‐1/L1 inhibitor. This analysis aimed to determine whether it is more cost‐effective to use sintilimab, a domestic anti‐PD‐1 drug in China, as a first‐line treatment than reserving it until second‐line.

Keywords: cell; metastatic squamous; first line; line; second line; advanced metastatic

Journal Title: Cancer Medicine
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.